title: Colchicine treatment of liver fibrosis.
abstract: OBJECTIVE
  Because of its antifibrotic and anti-inflammatory effects, colchicine has been proposed as a treatment for liver disease. The results from clinical trials have however been inconsistent. The aim of the present study was to evaluate the effect of colchicine in the treatment of patients with hepatic fibrosis of various etiologies.
  
  
  METHODS
  Thirty-eight patients were randomized to receive either colchicine 1 mg per day (n=21, group A) or no antifibrotic agent (n=17, group B). Treatment lasted for at least 12 months. Liver biopsy was performed prior to entry and after 12 months. Liver function tests, serum aminoterminal peptide of procollagen III (PIIINP) levels and CD4:CD8 ratio of peripheral blood T lymphocytes (PBTLs) were performed at baseline and bimonthly or every 4 months post-treatment.
  
  
  RESULTS
  Mean albumin serum levels increased 12 months post-treatment period only in group A (p<0.05). Mean serum PIIINP levels did not change significantly after 12 months of treatment in group A; in 7 patients a reduction in mean serum PIIINP levels was noticed during 24-month post-treatment follow-up period (p<0.05). At baseline, a correlation between focal or bridging necrosis and CD4:CD8 ratio of PBTLs was noticed in group A (p < 0.05). The mean serum CD4:CD8 ratio was increased after 12 months of colchicine treatment (p<0.05) associated with abrogation of this correlation; comparison between the two groups revealed increased CD4:CD8 ratio in group A at 12 months (p<0.05). The histological findings according to Knodell criteria in both groups remained unchanged after 12 months follow-up. The treatment was well tolerated in all patients.
  
  
  CONCLUSIONS
  Long-term colchicine treatment in patients with hepatic fibrosis appears to exert an anti-inflammatory, anti-fibrotic and immunomodulatory effect.
authors.affiliation: Division of Gastroenterology, 2nd Prop. Department of Internal Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, Macedonia, Greece.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Nikolaidis
authors.forename: Jannis
authors.initials: J
authors.lastname: Kountouras
authors.forename: Olga
authors.initials: O
authors.lastname: Giouleme
authors.forename: Valasia
authors.initials: V
authors.lastname: Tzarou
authors.forename: Olga
authors.initials: O
authors.lastname: Chatzizisi
authors.forename: Kaliopi
authors.initials: K
authors.lastname: Patsiaoura
authors.forename: Athanasios
authors.initials: A
authors.lastname: Papageorgiou
authors.forename: Maria
authors.initials: M
authors.lastname: Leontsini
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Eugenidis
authors.forename: Chrysanthos
authors.initials: C
authors.lastname: Zamboulis
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D002908:Chronic Disease; D003078:Colchicine / Q000627:therapeutic use*; D005260:Female; D006505:Hepatitis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D003078:Colchicine